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Schistosome infection contributes to cancer development, but the mechanisms are
still not well-understood. SjE16.7 is an EF-hand calcium-binding protein secreted from
Schistosoma japonicum eggs. It is a neutrophil attractant and macrophage activator
and, as such, plays an important role in the inflammatory granuloma response in
schistosomiasis. Here, we show that SjE16.7 binds to host cells by interacting with
receptors for advanced glycation end products (RAGE). This ligation leads to activation
of the NF-κB signaling pathway, an increase in the generation of reactive oxygen species,
and production of the pro-inflammatory cytokines IL-6 and TNF-α. Using a mouse model
of colorectal cancer, we demonstrate that intraperitoneal injection of SjE16.7 promotes
colorectal cancer progression along with systemic myeloid cell accumulation. Thus,
our results identify a new helminth antigen contributing to tumor development in the
mammalian host.
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INTRODUCTION
More than 15% of cancers in the world are caused by infectious agents (1, 2). Aside from viruses,
bacteria, and fungi, parasites are also important biological carcinogens. Schistosomiasis, caused
by infection with blood fluke trematodes of the genus Schistosoma, is one of the most important
human parasitic diseases across the world. More than 200 million cases of schistosomiasis are
currently estimated worldwide (3). Schistosomiasis is associated with development of urinary
bladder cancer, colorectal cancer, rectal cancer, and hepatocellular carcinoma (4). Schistosoma
haematobium has been classified as a definite carcinogen to human (group I carcinogen), and S.
japonicum is considered a possible carcinogen for human (group 2B carcinogen) (5). It is generally
accepted that chronic inflammatory processes and oxidative stress are responsible for the role of
schistosome infection in carcinogenesis (4). However, the identity of the carcinogenic parasite-
derived molecules as well as the underlying mechanisms responsible for tumor development are
still not well-understood.
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SjE16.7 is an EF-hand calcium-binding protein derived
from the eggs produced by S. japonicum. We have previously
demonstrated that SjE16.7 is recognized by the host immune
system, attracting neutrophils and initiating the inflammatory
response seen in schistosomiasis (6). SjE16.7 also promotes
chronic inflammation by inducing macrophage chemotaxis and
cytokine production, and it is involved in the development of
the schistosome egg granuloma (7). In mammalian cells, EF-
hand proteins, such as S100 proteins, are highly associated with
inflammation and tumorigenesis (8–10). They bind to receptors
for advanced glycation end products (RAGE), a multiligand
receptor of the immunoglobin family, and are involved in the
regulation of leukocyte trafficking and inflammation (11). RAGE
ligation results in the activation of a diverse range of signal
transduction cascades and downstream pathways, including NF-
κB, and the generation of ROS and acts as a key player in
bridging inflammatory processes and cancer development (11–
13). In this study, we show that the binding of SjE16.7 to
RAGE plays a critical role in inducing activation of myeloid
inflammatory cells. Furthermore, SjE16.7 promotes chronic
myeloid cell accumulation and colitis-associated colorectal
cancer development in an in vivo mouse model. Thus, our
results identify a new helminth antigen contributing to tumor
development in the mammalian host.
MATERIALS AND METHODS
Ethics Statement
The conducts and procedures involving animal experiments
were approved by the Animal Ethics Committee of Shanghai
Jiao Tong University School of Medicine (project number A-
2016-028) according to Regulations for the Administration of
Affairs Concerning Experimental Animals (approved by the State
Council of the People’s Republic of China) and Guide for the
Care and Use of Laboratory Animals (Department of Laboratory
Science, Shanghai Jiao Tong University School of Medicine,
laboratory animal usage license number SYXK 2013-0050,
certified by Shanghai Committee of Science and Technology).
Mice
C57BL/6 mice (male, 6–8 weeks old) were purchased from
Shanghai Laboratory Animal Center, Chinese Academy of
Sciences. Mice were housed in the Shanghai Jiao Tong University
School of Medicine Animal Care Facilities under specific
pathogen-free conditions.
Materials
Chemicals were purchased from Sigma-Aldrich Co. unless
otherwise noted. Ca2+, phosphate-buffered saline (PBS; pH
7.2), Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine
serum (FBS), penicillin/streptomycin, L-glutamine, and EDTA
were obtained from Life Technologies. Glutathione sepharose
4B was ordered from GE healthcare, Stockholm, Sweden.
Antibodies used in Western blot analysis included goat anti-
mouse RAGE antibody (R&D systems, Apolis, MN, USA), mouse
anti-GAPDH antibody (Sigma, Saint Louis, MO, USA), rabbit
anti-β-actin antibody (Cell Signaling Technology, Boston, MA,
USA), rabbit anti-GST antibody (Millipore, Bedford, MA, USA),
rabbit anti-RAGE1, anti-phosphor-IκB, Phospho-p65, total IκB
and p65 antibody (Cell Signaling Technology, Boston, MA,
USA), and HPR-conjugated anti-mouse or anti-rabbit IgG (Cell
Signaling Technology, Boston, MA, USA). FITC-conjugated
anti-mouse B220, APC-conjugated anti-mouse CD3, FITC or
PerCP-conjugated anti-mouse CD4, PE-conjugated anti-mouse
CD8, cFITC-conjugated anti-mouse CD11b, PerCP-conjugated
anti-mouse Gr-1 (Ly6C and Ly6G), PE-conjugated anti-mouse
Foxp3, FITC-conjugated anti-mouse IFN-γ, PE-conjugated anti-
mouse IL-4, PerCP-conjugated anti-mouse IL-17 and control
isotype antibodies used for flow cytometry were ordered from
eBioscience (San Diego, CA, USA).
Recombinant antigens (His-SjE16.7 from yeast expression
system, GST, GST-SjE16.7 from E. coli), GST, and GST-SjE16.7-
conjugated glutathione sepharose 4B beads were prepared by our
own lab as described previously.
Cell Culture
The murine RAW 264.7, human Caco-2, and SW480 (ATCC)
cell lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% heat-inactivated FBS, 2mM L-
glutamine, and 100 U/ml penicillin/streptomycin (D10).
To generate bone marrow–derived macrophages (BMDMs),
bonemarrow cells were harvested frommice and cultured in D10
with 50 ng/ml M-CSF for 7 days. The resting macrophages were
collected using 5mMEDTA in cold PBS. After centrifugation, the
cells were resuspended in D10, seeded on a plate, and rested for
24 h before functional assays. BMDMs were > 95% CD11b+ and
F4/80+ as determined by flow cytometry.
Conjugation of Proteins to FITC and
Staining of Cells
Purified proteins were conjugated to FITC using the FluoroTag
FITC conjugation kit (Sigma) as per the manufacturer’s protocol.
Incubation of FITC-tagged proteins and cells were done in the
presence of 1% non-fat dry milk in PBS for 20min at 4◦C,
followed by repeated washings before analysis by flow cytometry.
Flow Cytometry
For surface staining, cell suspensions (1× 106 cells) were washed
once in FACS buffer (0.5% BSA-PBS), incubated with antibodies
for 30min at 4◦C, followed by two washes with FACS buffer
and fixation using 0.5% paraformaldehyde/FACS buffer. For
intracellular staining, after the standard steps, cell suspensions
were washed twice in PBS containing 0.5% saponin (Sigma), then
incubated with antibodies in 0.3% saponin for 30min at 4◦C,
followed by two washes with FACS buffer and fixation using 0.5%
paraformaldehyde/FACS buffer. Foxp3 staining was performed
using Foxp3/Transcription Factor Staining Buffer Set according
to the manufacturer’s instructions (eBioscience, San Diego, CA,
USA). All antibodies were used at 1µg/ml. Flow cytometric
data was acquired on a BD FACS Calibur Flow Cytometer and
analyzed using FlowJo software.
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GST-Pulldown
RAW 264.7, Caco-2, and SW480 cell lysates were prepared
using lysis buffer (50mM HEPEs, 150mM NaCl, 1mM EDTA,
pH 7.0, 0.1% IGEPAL) supplemented with 1× complete
protease inhibitors mixture (Roche). Protein concentration was
determined by BCA assay (Pierce). GST pulldown was performed
using GST and GST-SjE16.7 sepharose beads. The cell lysates
were incubated with 30 µl GST or GST-SjE16.7 beads for 1 h
at 4◦C, followed by washing of the beads. Total cell lysates and
bead-bound proteins were subjected to Western blot.
Western Blot Analysis
Proteins were separated by 10–12% SDS-PAGE. Western
blotting was performed on nitrocellulose filter (Biorad). The
membranes were blocked for 1 h in TBST (10mM Tris pH
8.0, 150mM NaCl, 0.1% Tween 20) with 5% non-fat dry milk
and incubated with primary antibodies overnight, followed
by washing and incubation with HRP-conjugated secondary
antibodies. Enhanced chemiluminescence (ECL, Pierce) was used
as substrate, and the signals were analyzed by Luminescent
imager (ImageQuant Las 4000, GE Healthcare).
shRNA Knockdown of RAGE Expression
The constructs in pGMLV-SC5, containing RAGE-specific short
hairpin RNA (shRNA) sequences directed to mouse RAGE
mRNA (GeneBANK accession no. NM_007425) and non-specific
shRNA control vector were purchased from Genomeditech Co.
Ltd. (Shanghai, China). RAW 264.7 cells were transfected using
Attractene transfection reagent according to the manufacturer’s
instruction (QIAGEN). Cells were used for the experiments
24–48 h after transfection, and the RAGE expression level
following shRNA knockdown was assessed by real-time PCR and
Western blot.
Detection of Reactive Oxygen Species
(ROS)
ROS production by BMDMs was measured by a luminol-
dependent chemiluminescence assay, and 3 × 105 cells
were plated in a 96-well luminometer plate (Costar) and
prewarmed for 5min. Prewarmed His-SjE16.7, GST, or GST-
SjE16.7 (1µM) were added with luminol (100µM) and HRP
(20 U/ml) at the same time, and measurements started
immediately. Chemiluminescence was measured at 2.5-min
intervals for 30–60min with a luminometer (BioTek Synergy HT
microplate reader).
The ROS production of RAW 264.7 cells was detected
using 2′,7′-dichlorofluorescein diacetate (DCFDA). Cells were
incubated with the fluorogenic probe DCFDA for 30min
at 37◦C in 5% CO2. ROS levels were determined using a
microplate reader.
Real-Time Quantitative PCR
BMDMs or RAW 264.7 cells were stimulated with 1µM
recombinant His-SjE16.7, GST-SjE16.7, or control recombinant
protein GST in D10 for 2 h. Total RNA was isolated using
RNeasy Kits (Roche), and first strand cDNA was subsequently
synthesized with random hexamer oligonucleotides using
Invitrogen reverse transcriptase II. Real-time quantitative PCR
was carried out in an Applied Biosystems 7500 system using
Power SYBR Green PCR Master Mix (Applied Biosystems).
Thermocycler conditions comprised an initial holding at 50◦C
for 2min and a subsequent holding at 95◦C for 10min,
which was followed by a two-step PCR program at 95◦C for
15 s and 60◦C for 60 s for 40 cycles. Relative levels of gene
expression of IL-1β, IL-6, and TNF-α were determined using




IL-6 forward 5′- TAGTCAATTCCAGAAACCGCTATG -3′;
IL-6 reverse 5′- GTAGGGAAGGCCGTGGTTGT -3′;
TNF-α forward 5′- GACGTGGAACTGGCAGAAGAG -3′;
TNF-α reverse 5′- GCCACAAGCAGGAATGAGAAG -3′.
Induction of Colitis Associated Colon
Cancer (CAC) in Mice
The colitis-associated colon cancer model was induced with
dextran sodium sulfate (DSS) (36–50 kDa; MP Biomedicals, CA,
USA) and azoxymethane (AOM) (Sigma). Mice were injected
intraperitoneally (i.p.) with a single dose of 10 mg/kg AOM on
day 1. After the AOM injection, mice were given two cycles of
4% DSS (cycle 1: days 1–7; cycle 2: days 15–21) in the drinking
water, followed by normal drinking water until the end of the
experiment. Recombinant proteins (100 µg His-SjE16.7, GST-




Supernatants were collected for measurement of TNF-α and IL-6,
using ELISA kits (R&D Systems) according to the manufacturer’s
instructions. A standard curve was generated using known
amounts of the respective purified recombinant murine cytokine.
Statistical Analysis
Flow cytometry, chemiluminescence, 2′7′-dichoroluorescein
(DCFH or DCF), real-time PCR, and tumor number data were
analyzed by unpaired Student’s t-test using GraphPad Prism
software. Data are typically expressed as the mean ± SEM.
Significance parameters were set at p < 0.05.
RESULTS
RAGE Is the Receptor for SjE16.7 on Host
Cells
To investigate the mechanism by which SjE16.7 triggers host
cell activation, we analyzed whether SjE16.7 can bind to host
cells. FITC-labeled recombinant SjE16.7 or control GST proteins
were incubated with different host cells, and after removal of
unbound protein by extensive washing, the cells were analyzed
by flow cytometry. As shown in Figure 1A, SjE16.7 showed
robust binding to mouse macrophage cells (RAW 264.7), and
the MFI of SjE16.7-labeled cells was significantly higher than
that of control GST protein-labeled cells. Similar results were
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FIGURE 1 | SjE16.7 binds to RAGE. (A) FITC-labeled SjE16.7 or control FITC-GST protein binding to RAW 264.7, Caco-2, and SW-480 cells was measured by flow
cytometry. Pooled data from two independent experiments are shown. MFI, Mean Fluorescence Intensity. **p < 0.01 FITC-SjE16.7 group compared with FITC-GST
group. (B) RAW 264.7, Caco-2, and SW-480 cell lysates were prepared and pulled down with GST or GST-SjE16.7 sepharose beads. Protein on beads and in total
cell lysates was subjected to Western blot to determine the levels of bound RAGE. The experiments were repeated at least three times with similar results.
obtained using colorectal adenocarcinoma cells (Caco-2 and
SW480), demonstrating that SjE16.7 binds to mammalian host
cells more efficiently than control GST protein.
We then asked whether SjE16.7 can interact with RAGE
as other EF-hand proteins, and for this purpose, we used a
GST pulldown assay. Recombinant GST or GST-SjE16.7 proteins
were incubated with cell lysates from RAW 264.7, Caco-2, or
SW480 cells. After washing of the beads, the bound proteins
were subjected to Western blot analysis. As shown in Figure 1B,
SjE16.7 interacted with RAGE from mammalian cells.
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FIGURE 2 | SjE16.7 promotes ROS production via RAGE. (A) BMDMs were stimulated with 1µM eukaryotic recombinant protein His-SjE16.7 or prokaryotic
recombinant protein GST-SjE16.7 GST, or GST control. ROS production was measured by chemiluminescence assay as described in section Materials and Methods.
Data shown are profiles of the kinetics of ROS production. RLU, relative light unit. (B) Area under curve (AUC) in (A) is shown. (C) The expression of RAGE in RAW
264.7 cells was knocked down by lentivirus-mediated RNA interference (RNAi), and then the effect of SjE16.7 on ROS production was determined by DCFH assay
(left panel). RAGE expression levels were measured by Western blot (right panel). Statistical analysis was performed on pooled data from three independent
experiments. *p < 0.05, **p < 0.01 compared with indicated control group.
SjE16.7 Promotes ROS Production via
RAGE
In order to investigate if the interaction between SjE16.7
and RAGE resulted in ROS production, we measured ROS
production in SjE16.7 treated cells. Using a horseradish
peroxidase (HRP)-dependent chemiluminescence assay, we
found that both eukaryotic recombinant His-SjE16.7 and
prokaryotic recombinant GST-SjE16.7 significantly increased
ROS production in bone marrow–derived macrophages
(BMDMs) compared to medium control or GST control protein
(Figures 2A,B). To further confirm the importance of RAGE
in SjE16.7-induced ROS production, we utilized a RAGE
knockdown. The expression of RAGE in RAW 264.7 cells was
blocked by lentivirus-mediated RNA interference (RNAi), and
the effects of SjE16.7 on ROS production was determined by
DCFH assay. The results shown in Figure 2C demonstrate
that treatment of RAW 264.7 cells with SjE16.7 increased ROS
production; however, when using RAGE knockdown cells, ROS
production was significantly reduced back to background levels.
Taken together, our results demonstrate that the interaction
of SjE16.7 and RAGE results in increased ROS production by
myeloid cells.
SjE16.7 Induces NF-κB Signaling Activation
and Proinflammatory Cytokine Production
via RAGE
We next analyzed the effects of SjE16.7 on IκB and NF-κB
activation in mouse BMDMs. Phosphorylated and total IκBα
were determined by Western blot analysis. As shown in
Figure 3, eukaryotic His-SjE16.7 and prokaryotic GST-SjE16.7
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FIGURE 3 | SjE16.7 induces NF-κB signaling activation and proinflammatory cytokine production. (A) BMDMs were stimulated with 1µM eukaryotic recombinant
protein His-SjE16.7 or prokaryotic recombinant protein GST-SjE16.7, or GST control, for the indicated times, and the levels of phospho-IκBα, total IκBα, phospo-p65,
(Continued)
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FIGURE 3 | and total p65 were determined by Western blot analysis. Results are representative of three experiments performed. (B) BMDMs were stimulated with
1µM recombinant His-SjE16.7, GST-SjE16.7, or control GST protein for 2 h, and IL-6 and TNF-α mRNA levels were determined by real-time PCR. (C) BMDMs were
stimulated with 1µM recombinant His-SjE16.7, GST-SjE16.7, or control GST protein for 24 h, and IL-6 and TNF-α protein levels in culture supernatant were
determined by ELISA. Statistical analysis was performed on pooled data from two to four independent experiments. **p < 0.01.
induced a rapid phosphorylation of IκB and degradation of
total IκB protein. Moreover, both eukaryotic His-SjE16.7 and
prokaryotic GST-SjE16.7 induced more phosphorylated p65
subunit of NF-κB than medium control or GST control
protein (Figure 3A). The stimulation of BMDMs with
SjE16.7 led to a significant increase in proinflammatory
cytokine expression (IL-6 and TNF-α) at both mRNA
and protein levels (Figures 3B,C). However, when using
RAGE knockdown RAW 264.7 cells, there was less NF-κB
signaling activation and proinflammatory cytokine production
compared to the control cells (Figure 4), suggesting that NF-
κB activation and the resulting pro-inflammatory cytokine
release induced by SjE16.7 was mediated through its interaction
with RAGE.
SjE16.7 Promotes Increased Incidence of
Colitis-Associated Colorectal Cancer and
Splenic Myeloid Cell Accumulation
In order to investigate if SjE16.7 contributes to inflammation-
induced tumor development, we analyzed the role of SjE16.7
in a mouse model of colitis-associated colorectal cancer (CAC).
CAC was induced in mice using a single dose of AOM followed
by repeated cycles of DSS. Separate groups of AOM-DSS
mice were treated with vehicle control (PBS), control protein
(GST), GST-SjE16.7, or His-SjE16.7 (Figure 5A). Animals in
all groups exhibited weight loss and diarrhea during the
acute phase, which resolved within 2 weeks after AOM/DSS
treatment (Figure 5B). Mice treated with eukaryotic His-SjE16.7
and prokaryotic GST-SjE16.7 did not show any significant
difference in weight loss or clinical signs of inflammation
compared to the controls (Figures 5B,C). However, 14 weeks
after initiation, the incidence of colorectal tumors was increased
in SjE16.7-treated animals with 100% incidence in the His-
SjE16.7 treated group and 90% incidence in the GST-SjE16.7
treated group although the tumor incidences in the PBS group
and GST control group were 50 and 70%, respectively. SjE16.7
treatment resulted in significantly more large tumors (>2mm)
than in the control groups (Figure 5D). As expected from
their increased tumor numbers and tumor sizes, His-SjE16.7-
and GST-SjE16.7-treated mice had a significant increase in
the frequency of inflammatory myeloid cells (CD11b+) in
their spleens but significantly lower frequency of CD4+ and
CD8+ T cells (Figure 6). Further analysis of myeloid and T-
cell subsets showed that the frequency and numbers of Gr-
1hi myeloid cells was significantly higher in the His-SjE16.7
and GST-SjE16.7 treated mice, and the frequency and numbers
of SiglecF+ eosinophils, IFN-γ+, IL-4+, and IL-17+ CD4+
T helper cells were similar between the antigen-treated and
control groups (Figures 7, 8). The number of FoxP3+CD4+
T regulatory cells, however, was significantly increased in
the His-SjE16.7 and GST-SjE16.7 treated mice, compared to
controls (Figure 8).
Taken together, the data demonstrate that SjE16.7 exposure
leads to increased colorectal tumor development and is associated
with a higher frequency of myeloid inflammatory cells in
the spleen.
DISCUSSION
Several parasitic infections are associated with carcinogenesis
and human malignancy (4). The helminth diseases
opisthorchiasis and clonorchiasis are strongly associated
with cholangiocarcinoma, and schistosomiasis is associated
with bladder carcinoma and colorectal cancer, depending
on the schistosome species. However, some parasites may
also act as negative regulators of cancer. This includes
the activation of NK cells and CD8+ T cells seen during
Toxoplasma gondii infection and the pro-apoptotic effects
of Trypanosoma cruzi infection as well as the Kunitz type
protease inhibitor from Echinococcus granulosus, which was
shown to induce tumor cell apoptosis in a mouse melanoma
model (14, 15).
Although infection with S. japonicum is a known risk
factor for the development of colorectal cancer, the exact
etiopathogenesis of schistosome-associated colorectal cancer
remain enigmatic (16–18). Here, we provide evidence that
the schistosome SjE16.7 protein may contribute to colorectal
cancer progression. This conclusion is based on the following
observations: (a) SjE16.7 binds to RAGE, which is known to have
a key role in inflammation-associated cancer development. (b)
SjE16.7-RAGE ligation leads to an increase in ROS generation,
NF-κB signaling activation, and pro-inflammatory cytokine
production, which all contribute to establishing a protumorigenic
environment. (c) In vivo mouse experiments demonstrate that
intraperitoneal injection of SjE16.7 promote colitis-associated
colorectal cancer progression along with systemic myeloid
cell accumulation.
RAGE is a pattern recognition receptor that can bind multiple
ligands (19). Among these ligands, the S100 proteins are small
calcium-binding proteins with EF-hand motifs prevalent in a
variety of inflammatory diseases and known contributors to
cancer cell biology (10). Similar to S100 proteins, SjE16.7 is
a small calcium-binding protein with 2 EF-hand motifs. We
have previously demonstrated that SjE16.7 is a potent myeloid
cell activator used by the schistosome egg to mediate the
inflammatory response needed to facilitate the passage of eggs
through tissues (6, 7). In this study, we have established that
SjE16.7 binds to RAGE, leading to activation of downstream
signaling pathways. There is evidence that the S100 proteins
form subgroups that bind to different sites on RAGE, resulting
in triggering of distinct cellular pathways (11). The binding
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FIGURE 4 | RAGE is essential for SjE16.7-induced NF-κB signaling activation and proinflammatory cytokine production. (A) The expression of RAGE in RAW 264.7
cells was knocked down by lentivirus-mediated RNA interference (RNAi). The cells were then stimulated with 1µM eukaryotic recombinant protein His-SjE16.7 or
prokaryotic recombinant protein GST-SjE16.7 for the indicated times. The levels of phospho-IκBα and total IκBα, phospo-p65 and total p65 were determined by
Western blot. Results are representative of two experiments. (B) RAGE knockdown RAW 264.7 cells or control cells were stimulated with 1µM recombinant
His-SjE16.7 or GST-SjE16.7 for 2 h. IL-6 and TNF-α mRNA levels were determined by real-time PCR. Statistical analysis was performed on pooled data from three
independent experiments. *p < 0.05, **p < 0.01.
domain of the receptor or the biding epitope on SjE16.7 is
currently unknown, and future studies are necessary to increase
our detailed understanding of the interaction between SjE16.7
and mammalian cells.
RAGE is expressed on many different cell types (13, 20–
23). Considering that SjE16.7 is a potent innate immune
cell activator and that chronic inflammatory processes are
essential in schistosomiasis-associated cancer (17, 24), we focused
on SjE16.7-induced RAGE signaling in innate immune cells.
We found that SjE16.7-RAGE ligation on the macrophage
surface triggers the generation of ROS and the release of
pro-inflammatory cytokines (IL-6 and TNF-α) and that the
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FIGURE 5 | SjE16.7 promotes colon-rectal cancer development in mice. (A) Illustration of the experimental layout of CAC induction and in vivo treatment with
recombinant protein His-SjE16.7, GST-SjE16.7, and GST control. (B) Change in body weight over time is expressed as the percentage of the initial body weight.
Pooled data from four independent experiments is shown. n = 15–20 per group. (C) Colon length was measured on day 10, n = 5 per group. (D) Colonic neoplasms
were photographed and numbers of macroscopic neoplasms were counted individually at week 14. Results are presented as pooled data from three independent
experiments. **p < 0.01, ***p < 0.001 compared with the indicated control group.
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FIGURE 6 | SjE16.7 administration increases the frequency of myeloid cells in the spleen of the CAC mouse model. Splenocytes were isolated from His-SjE16.7,
GST-SjE16.7, GST-control, or PBS control-treated mice 14 weeks post-CAC induction. Frequencies of splenic B220+, CD3+, CD4+, CD8+, and CD11b+ cells were
determined by flow cytometry. The frequency and number of cells in spleen is presented as the mean ± SEM of 12–13 individual mice per group. *p < 0.05, **p <
0.01, ***p < 0.001 compared with the indicated control group.
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FIGURE 7 | SjE16.7 administration increases CD11b+Gr-1hi myeloid cells in the spleen of the CAC mouse model. Splenocytes were isolated from His-SjE16.7,
GST-SjE16.7, GST-control, or PBS control treated mice 14 weeks post-CAC induction. (A) Representation of the flow cytometry gating strategy for the determination
of splenic CD11b+ myeloid cells subpopulations. (B) Frequency and absolute number of Gr-1hi and Siglec F+ cells within the CD11b+ myeloid population was
determined by flow cytometry. The frequency and number of CD11b+Gr-1hi and CD11b+Siglec F+ cells in spleen are presented as the mean ± SEM of six to seven
individual mice per group. *p < 0.05, **p < 0.01 compared with indicated control group.
NF-κB pathway is involved in the RAGE-dependent macrophage
activation. Thus, our results are consistent with previous reports
suggesting that RAGE is a central mediator of innate immune
responses (20). Our study also implies that SjE16.7 may be
involved in schistosomiasis-associated cancer progression via
RAGE ligation. RAGE signaling is known to drive the strength
and maintenance of an inflammatory response and, as such,
serve as a key player in bridging chronic inflammation and
Frontiers in Immunology | www.frontiersin.org 11 August 2020 | Volume 11 | Article 1767
Wu et al. SjE16.7 Promotes Tumor via RAGE
FIGURE 8 | SjE16.7 administration increases splenic FoxP3+ CD4+ T cell numbers in CAC mice treated with or without SjE16.7. Splenocytes were isolated from
His-SjE16.7, GST-SjE16.7, GST-control, or PBS control treated mice 14 weeks post-CAC induction, and intracellular staining was performed as described in Materials
and Methods. The frequencies of IFN-γ+, IL-4+, IL-17+, and Foxp3+ cells within the CD4+ population were determined by flow cytometry. The frequency and
absolute number of CD4+ IFN-γ+, CD4+ IL-4+, CD4+ IL-17+, and CD4+Foxp3+ cells in spleens are presented as the mean ± SEM of six to seven individual mice per
group. **p < 0.01, compared with indicated control group.
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cancer (25), and using the murine CAC model, we found that
in vivo treatment with SjE16.7 does indeed promote colorectal
tumor progression. The development of colon cancer is a
multistep process that is regulated by various intrinsic and
extrinsic cellular signals (26, 27), and activation of RAGE
signaling in innate immune cells by SjE16.7 may result in the
establishment of a protumorigenic microenvironment through
the secretion of pro-inflammatory cytokines such as IL-6,
and TNF-α. It should be noted, however, that there is also
evidence that IL-6 and TNF-a may be antitumorigenic at higher
concentrations, suggesting that the local concentration of these
cytokines in the tumormicroenvironment is a key factor in tumor
progression (28–32).
Our CAC model experiments demonstrated that SjE16.7-
treated mice had increased numbers of tumors and increased size
of tumors along with an increased frequency of CD11b+ myeloid
cells in the spleen. The increase in myeloid cell frequencies was
accompanied by a decrease in T cell frequencies for both CD4+
and CD8+ T cells. Accumulation of myeloid-derived suppressor
cells (MDSCs) is one of the major immunological abnormalities
in cancer resulting in T cell tolerance and suppression
of antitumor immune response. MDSCs are CD11b+Gr1+
cells (CD11b+Ly6G+ or CD11b+Ly6C+) with the ability to
prevent T cell activation, and they have been identified in
the spleen, blood, and tumor tissues of tumor-bearing mice
(21, 33, 34). Importantly, it has been reported that RAGE
signaling contributes to the development of MDSCs, and that
RAGE stimulation of MDSCs promote their migration and
accumulation through NF-κB signaling pathways (35, 36). In
our study, SjE16.7 treated mice had higher frequencies and
cell numbers of CD11b+Gr-1hi myeloid cells compared to
the control groups. This phenotype suggests that SjE16.7 may
promote MDSC development and/or accumulation via RAGE
ligation. The frequencies and absolute numbers of splenic
Th1, Th2, and Th17 cells were no different between groups
treated with or without SjE16.7 in our CAC model. The
absolute number of splenic Treg cells, however, was significantly
increased in the SjE16.7-treated groups. It has previously been
reported that MDSC promotes the induction of Tregs and that
the two cell types may collaborate in suppressing antitumor
immunity (37). Further experiments combining in vitro and
cell function assays are necessary to establish whether this is
the case. Moreover, it is important to establish whether this
is a specific mechanism for colorectal cancer or it could also
be similar in other types of cancer, such as schistosomiasis-
associated liver cancer. In addition to immune response,
multiple other factors, such as oncogene activation, inhibition
of tumor suppressors, modifications of normal microRNA
expression patterns, alterations to the epigenetic landscape as
well as the intestinal microbiota are also involved in colorectal
cancer development (38). RAGE is present on epithelial and
mesenchymal cells and is known to play a role in the development
of sporadic intestinal tumors (26). Our in vitro data demonstrate
that SjE16.7 binds to RAGE on epithelial cells, however, whether
SjE16.7 also activates RAGE signaling pathways in epithelial cells,
similar to that seen in myeloid cells, and if so, whether this
contribute to its protumorigenic function in vivo still needs to
be determined.
A number of mouse models are available for the study of
colon carcinogenesis (39), including transgenic and chemically
induced models. The latter group include in vivo treatments
with chemical agents, such as methylnitrosourea (MNU), 2-
amino-1-methyl-6-phenylimidazol [4,5-b]pyridine (PhIP), or
1,2-dimethylhydrazine (DMH) (40). However, among the
chemically induced mouse tumor models, the combination of
a single dose of AOM followed by 1 week exposure to the
inflammatory agent DSS has proven to dramatically shorten
the time for tumor development. Because of this, together with
its high reproducibility and potency as well as the simple and
affordable mode of application, the AOM/DSS has become a
superior model for studying colon carcinogenesis (39). The
AOM/DSS model is particularly useful when the focus is on
tumor progression driven by colitis as an inflammatory disease
(41). In this study, we used the AOM/DSS model to demonstrate
that SjE16.7 contributes to this form of inflammation-induced
cancer. Future studies will be aimed at establishing if SjE16.7 also
acts as an oncogenic driver in other types of cancer models.
In addition to the association of schistosomiasis infection
and colorectal cancer, infections with the urogenitary species,
S. haematobium, has been correlated with the occurrence of
bladder carcinoma (42). According to the genome information
of schistosomes, there are homologs of SjE16.7 in both S.
haematobium (70% identity) and S. mansoni (SmE16, 70%
identity) (43, 44). It has been reported that SmE16 is one of the
more abundant S. mansoni egg secreted proteins; however, there
is currently limited information available regarding the specific
roles of the S. mansoni and S. haematobium homologs of SjE16.7,
and more research in this field is needed.
In conclusion, our study demonstrates a key role for the
schistosome egg protein SjE16.7 in driving pro-inflammatory
innate responses by acting as a ligand for RAGE. In addition, our
data provide additional insight into the role played by SjE16.7 in
promoting tumor progression.
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AUTHOR’S NOTE
Infections may promote cancer development because infectious
agents induce procarcinogenic inflammatory processes within
their host. Schistosomiasis, caused by infection with blood
fluke trematodes of the genus Schistosoma, is one of the
most important human parasitic diseases across the world.
Schistosomiasis is associated with urinary bladder cancer,
colorectal cancer, rectal cancer, and hepatocellular carcinoma,
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but the underlying mechanisms are still not well-understood.
SjE16.7 is a calcium binding protein secreted from Schistosoma
japonicum eggs. We have previously demonstrated that SjE16.7
is a neutrophil attractant and macrophage activator and initiates
the inflammatory granuloma responses in schistosomiasis. In this
study, we report that SjE16.7 binds to host cells by interacting
with receptors for advanced glycation end products (RAGE). This
ligation leads to an increase in the generation of reactive oxygen
species and production of pro-inflammatory cytokines. In vivo
experiments demonstrate that SjE16.7 treatment promotes
colitis-associated colorectal cancer progression along with
systemic myeloid cell accumulation. Our data suggest that
SjE16.7 is associated with colorectal cancer due to the
activation of procarcinogenic inflammatory processes. Thus, our
results identify a new helminth antigen contributing to tumor
development in the mammalian host.
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